ERNA Stock Overview
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Eterna Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.96 |
| 52 Week High | US$3.45 |
| 52 Week Low | US$0.84 |
| Beta | 8.16 |
| 1 Month Change | -17.65% |
| 3 Month Change | 9.50% |
| 1 Year Change | -34.89% |
| 3 Year Change | -99.61% |
| 5 Year Change | n/a |
| Change since IPO | -97.94% |
Recent News & Updates
Shareholder Returns
| ERNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.3% | -2.5% | -3.2% |
| 1Y | -34.9% | -3.7% | 19.3% |
Return vs Industry: ERNA underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: ERNA underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| ERNA volatility | |
|---|---|
| ERNA Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ERNA's share price has been volatile over the past 3 months.
Volatility Over Time: ERNA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 8 | Sanjeev Luther | eternatx.com |
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
Eterna Therapeutics Inc. Fundamentals Summary
| ERNA fundamental statistics | |
|---|---|
| Market cap | US$11.58m |
| Earnings (TTM) | -US$21.68m |
| Revenue (TTM) | US$68.00k |
155.9x
P/S Ratio-0.5x
P/E RatioIs ERNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERNA income statement (TTM) | |
|---|---|
| Revenue | US$68.00k |
| Cost of Revenue | US$236.00k |
| Gross Profit | -US$168.00k |
| Other Expenses | US$21.52m |
| Earnings | -US$21.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.01 |
| Gross Margin | -247.06% |
| Net Profit Margin | -31,888.24% |
| Debt/Equity Ratio | 303.3% |
How did ERNA perform over the long term?
See historical performance and comparison